



**Canada's Drug Agency**  
**L'Agence des médicaments du Canada**  
Drugs. Health Technologies and Systems. Médicaments, technologies de la santé et systèmes.

**Proposed Project Scope**

# **Cabozantinib for locally advanced or metastatic extra-pancreatic or pancreatic neuroendocrine tumours**

Date: January 2025

## Background and Rationale

CDA-AMC received a request from public drug programs for a Non-Sponsored Reimbursement Review of cabozantinib for locally advanced or metastatic extra-pancreatic (ep-NET) or pancreatic neuroendocrine tumours (pNET).

**Table I: Policy Questions**

Item	Policy Question
1	Should cabozantinib be publicly reimbursed for locally advanced or metastatic ep-NET or pNET?

**Table II: Products Available in Canada**

Product	Manufacturer
Cabozantinib	Ipsen Biopharmaceuticals Canada Inc

## Project Description

**Table III: Project Scope**

Criteria	Description
Population	Patients with locally advanced or metastatic ep-NET or pNET
Intervention(s)	Cabozantinib
Comparators	Somatostatin analogs: lanreotide or octreotide Everolimus Sunitinib Streptozocin/doxorubicin/5-fluorouracil Capecitabine/temozolomide 177Lu-DOTATATE
Outcomes	Progression-free survival Objective response Overall survival Safety

**Table IV: Research Questions**

Item	Policy Question
1	What is the effectiveness of cabozantinib for locally advanced or metastatic ep-NET or pNET?
2	What are the harms associated with cabozantinib for locally advanced or metastatic ep-NET or pNET?
3	What is the expected cost of cabozantinib for locally advanced or metastatic ep-NET or pNET vs. other reimbursed regimes?

## **Key Project and Protocol Components**

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

## **Status of the Document**

This proposed project scope is being posted for information.